Credit: Canva
Cancer is a large group of diseases that can start in almost any organ or tissue of the body when abnormal cells grow uncontrollably, and go beyond their usual boundaries to invade adjoining parts of the body. According to the World Health Organization (WHO), it is the second most common cause of death globally, accounting for millions of deaths every year. Lung, prostate, colorectal, stomach and liver cancer are the most common types of cancer in men, while breast, colorectal, lung, cervical and thyroid cancer are the most common among women. However, these are not necessarily the deadliest forms of cancer.
What makes cancer the deadliest depends upon how many people have it and what percentage of those people actually survive. Cancer researchers determine this on the basis of five-year relative survival. This is the percentage of people who are expected to survive the effects of a given cancer, excluding their risk of other possible causes of death, for five years past a diagnosis. It is also important to note that what makes cancer really deadly is that practically no cure for it. A cure for cancer would imply that there are no cancerous cells remaining in the body.
Here are the 5 deadliest cancers in the U.S., according to SEER five-year relative survival data for cases diagnosed between 2014 and 2020.
1. Pancreatic cancer occurs when cells in your pancreas, a gland in your abdomen that aids digestion, mutate and multiply out of control, forming a tumour. Major risk factors include smoking, obesity, diabetes, chronic pancreatitis, certain genetic mutations and environmental chemical exposure.
2. Esophageal cancer develops in the oesophagus, which is the tube that connects your throat to your stomach.
3. Liver cancer and intrahepatic bile duct cancer originate in the liver or bile ducts, often linked to hepatitis infections, heavy alcohol use, obesity, and aflatoxin exposure.
4. Lung and bronchus cancer primarily caused by smoking, secondhand smoke, and environmental pollutants, affects the lungs and airways, making it the leading cause of cancer death in the US.
5. Acute myeloid leukaemia (AML) is an aggressive blood and bone marrow cancer that progresses rapidly, often linked to genetic mutations, radiation exposure, and certain chemicals.
ALSO READ: Why Are Lifestyle Factors Making Millennials Vulnerable To Cancer?
Credit: iStock
Ivonescimab, a much-anticipated lung cancer drug developed by China's Akeso in partnership with US-based Summit Therapeutics, has been rejected by the US Food and Drug Administration (FDA).
The drug, a PD-1 x VEGF bispecific antibody, was being evaluated in combination with chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer had progressed after treatment with EGFR-targeted drugs.
The FDA's decision came after a late-stage clinical trial showed that ivonescimab significantly delayed disease progression but failed to demonstrate a statistically significant improvement in overall survival (OS), a key measure of how long patients live after starting treatment.
In its Complete Response Letter (CRL), the regulator said the improvement in progression-free survival (PFS), without a statistically significant OS benefit, "did not establish a favorable benefit-risk profile to support approval".
Also read: 1 In 5 US Lung Cancer Patients Never Smoked: Report Highlights Hidden Risk Factors
The FDA's decision was based on findings from the Phase III HARMONi trial, which compared ivonescimab plus platinum-based chemotherapy with chemotherapy alone.
The combination reduced the risk of disease progression or death by 48% compared with chemotherapy alone, meeting the trial's primary PFS endpoint.
However, the primary overall survival analysis did not demonstrate a statistically significant benefit. This meant that although patients receiving ivonescimab experienced a delay in their cancer worsening, the trial did not establish that the treatment helped them live significantly longer.
Summit subsequently submitted updated analyses based on longer follow-up. The company said these showed a consistent survival benefit across Asian and Western patient groups.
However, the FDA maintained that the available evidence did not establish the survival benefit needed to support approval.
Ivonescimab is an investigational PD-1 x VEGF bispecific antibody designed to target two proteins involved in cancer growth and immune evasion.
PD-1 is an immune checkpoint protein that cancer cells can exploit to evade immune attacks. Blocking this pathway can help the immune system recognize and attack cancer cells.
VEGF, meanwhile, helps tumors develop new blood vessels that supply oxygen and nutrients, supporting their growth. Blocking VEGF can interfere with this process.
By targeting both pathways, ivonescimab combines two approaches to fighting cancer: helping the immune system attack tumors and disrupting the blood supply that supports their growth.
The drug is administered through an intravenous infusion.
Ivonescimab had attracted considerable attention because of its dual-targeting approach and potential applications beyond lung cancer.
Its developers had hoped that the drug could eventually challenge Merck's Keytruda, one of the world's best-selling cancer medicines.
Several major pharmaceutical companies, including Merck and Pfizer, are also exploring therapies that combine immune checkpoint inhibition with VEGF targeting.
However, cancer researchers have cautioned against assuming that promising early results will translate into broad clinical benefits across different cancer types.
The FDA's rejection concerns a specific lung cancer indication and does not automatically determine the outcome of ivonescimab trials in other cancers.
Despite the regulatory setback, ivonescimab's development programme continues.
Summit is evaluating the drug in several other cancers, including non-small cell lung cancer, colorectal cancer, urothelial cancer and renal cell carcinoma.
The company and Akeso have reported five positive Phase III studies across their development programmes and have said they remain committed to advancing the drug.
Credit: AI-generated image
An experimental weight loss injection developed in China has produced an average weight reduction of 17.7% over 48 weeks in adults who are overweight or obese, raising the possibility of another contender entering in the rapidly expanding obesity drug market.
The drug, called ribupatide, was evaluated in a Phase 3 clinical trial published in JAMA recently. Researchers found that participants receiving the highest dose lost nearly one-fifth of their starting body weight in 11 months.
The randomised trial involved 567 adults with overweight or obesity across 55 medical centres in China. Participants did not have diabetes and their average age was 34 years.
Researchers randomly assigned them to receive once-weekly injections of ribupatide at doses of 2 mg, 4 mg or 6 mg, or a placebo. All participants also received lifestyle counselling. After 48 weeks, the average weight reduction was:
The researchers also examined how many participants lost at least 5% of their starting weight. This threshold was achieved by 68.1% of those receiving 2 mg, 88% in the 4 mg group and 85.7% in the 6 mg group, compared with 16% of participants receiving placebo.
Notably, weight loss had not clearly plateaued in the two higher-dose groups by the end of the study. This suggests that a longer treatment period may reveal further reductions.
Ribupatide, also known as HRS9531, is a dual-acting injectable medication that targets the GLP-1 and GIP hormones. These gut hormones help regulate appetite, digestion and blood glucose levels. By activating their receptors, the drug helps reduce hunger and increase feelings of fullness, helping people consume fewer calories.
This is similar to that of tirzepatide, the active ingredient in Eli Lilly's Mounjaro and Zepbound. Both medicines target GLP-1 and GIP receptors.
The trial results have drawn comparisons with existing weight loss drugs like Mounjaro and Wegovy. However, the comparisons need to be interpreted carefully.
In the SURMOUNT-1 trial, tirzepatide produced average weight loss of up to 20.9% after 72 weeks in adults with obesity or overweight without diabetes. Semaglutide 2.4 mg, marketed as Wegovy, produced an average reduction of 14.9% after 68 weeks in the STEP 1 trial.
Ribupatide's highest-dose group recorded 17.7% weight loss after 48 weeks. But these results come from separate clinical trials. A direct comparison would be needed to determine how ribupatide performs against tirzepatide or semaglutide.
Digestive problems were the most frequently reported side effectsin the ribupatide trial. Gastrointestinal side effects occurred in 47.9% of participants receiving the 2 mg dose, 58.2% in the 4 mg group and 63.1% in the 6 mg group. This compared to 23.1% of those receiving placebo.
Reported problems included nausea, vomiting and diarrhoea. Most were mild or moderate according to the findings.
The study had its limitations as the participants were relatively young, which means the findings may not apply equally to older adults. Additionally, the 48-week treatment period may not have captured the full effects of the higher doses. The study's smaller body-composition assessment also did not measure muscle strength.
Ribupatide is an investigational treatment and is not yet an approved weight-loss medication for routine use.
Credit: AI-generated image
The United States has lost its measles elimination status after more than a year of sustained transmission, marking a major setback for a public health achievement the country obtained in 2000.
The decision by the Pan American Health Organization (PAHO) comes after a sharp rise in infections as the US reported more than 5,400 measles cases in 2026. PAHO is expected to formally announce the decision on November 17.
According to the US Centers for Disease Control and Prevention (CDC), the country had recorded 5,412 cases as of November 15, resulting in more than 590 hospitalisations and at least six deaths. Some states have reported additional fatalities. Cases have been confirmed in 45 states and Washington, DC.
The United States had maintained its measles elimination status for more than 25 years. However, outbreaks that began in 2025 continued spreading into 2026. Approximately one-third of this year's cases were linked to those ongoing outbreaks.
Measles elimination does not mean a country has no cases of the disease. It means that local transmission has been interrupted and that occasional outbreaks do not lead to sustained community spread.
Under the World Health Organization's definition, a country loses elimination status when it cannot stop continuous local transmission for at least 12 months.
The United States first achieved measles elimination status in 2000, after decades of vaccination efforts dramatically reduced infections. Imported cases and smaller outbreaks still occurred, but public-health measures and vaccination coverage helped contain them.
The current situation is different because the virus has continued circulating through communities for more than a year, creating ongoing chains of transmission.
CBS News medical correspondent Dr Céline Gounder explained the implications, "It means that we're at risk of being exposed to measles and getting measles if we're not vaccinated," Gounder said. "It means ERs and pediatricians need to consider measles in anyone with a fever and rash, whether they've traveled overseas or not. And we may now become an exporter of measles to other countries."
Also read: US Measles Cases Cross 5,000 For First Time Since 1991; Country Risks Losing Elimination Status
Declining childhood vaccination coverage has left more communities vulnerable to outbreaks. Measles is among the most contagious infectious diseases, and the virus can spread rapidly when it enters populations with gaps in immunity.
According to CDC data, 96% of people infected in 2026 were either unvaccinated or had an unknown vaccination status. Only 2% of reported cases were among people who were fully vaccinated.
The country recorded 2,242 cases in 2025, its highest annual total in more than three decades at the time. The number has more than doubled in 2026.
Pennsylvania has reported the largest outbreak, with more than 1,500 cases and seven deaths this year. Wisconsin has reported two child deaths, while New York recorded its first measles death in more than 30 years.
People who have not received the measles vaccine are at the greatest risk of infection. However, infants who are too young to be vaccinated, pregnant women and people with weakened immune systems are the most vulnerable.
Measles can cause complications like pneumonia and encephalitis or inflammation of the brain. In some cases, it can lead to permanent neurological complications, hearing loss and death.
Children who have not received the recommended doses of the measles, mumps and rubella (MMR) vaccine are especially vulnerable.
The CDC recommends two doses of the MMR vaccine. According to the public health experts, two doses are approximately 97% effective against measles.
Losing elimination status does not mean the country cannot regain it. However, sustained efforts to interrupt transmission will be necessary.
PAHO recommends maintaining measles vaccination coverage of at least 95%, alongside strong disease surveillance, laboratory testing and rapid outbreak response. Dr Omer Awan, an epidemiologist and public health contributor for Forbes, explained the importance of vaccination.
"It's frustrating and heartbreaking ... because we have the tools to fight this. The tool is the MMR vaccine, which we know is 97% effective at preventing the onset of measles," Awan said.
© $2026 Times Horizon Private Limited